Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate Cancer

Abstract Objectives Both normal and pathological growth of the prostate is dependent on dihydrotestosterone (DHT) synthesis, which is catalysed by two 5α-reductase (5αR) isoenzymes, 5αR1 and 5αR2, of which only 5αR2 has traditionally been viewed as important in the prostate. The objective of this study was to evaluate the role of both isoenzymes during development/progression of prostate cancer. Methods A thorough literature search was performed with the MEDLINE database to identify studies that have assessed expression of 5αR1/2 in prostate tissue. Results DHT suppression data for the 5αR2-specific inhibitor, finasteride, and the dual 5αR1/2 inhibitor, dutasteride, show that both isoenzymes are active in benign prostate. Furthermore, immunostaining studies have shown that 5αR1 expression increases and 5αR2 expression decreases in prostatic intraepithelial neoplasia (PIN) and prostate cancer, compared with nonmalignant prostate tissue. Both isoenzymes appear increased in high-grade compared with low-grade localised cancer. Dual inhibition of both isoenzymes with dutasteride may, therefore, be effective in preventing or delaying the growth of prostate cancer. The 4-yr REduction by DUtasteride of prostate Cancer Events (REDUCE) trial is underway to test this hypothesis. Androgen-withdrawal therapy can reverse prostate tumour growth by reducing circulating testosterone. However, 5αR-catalysed DHT synthesis within the prostate can continue and most tumours eventually develop resistance to androgen-deprivation therapy. Full assessment of the role of a 5αR inhibitor in this scenario is warranted. Conclusions The consensus of evidence to date shows that 5αR1 is present in the prostate, and that levels are higher in malignant compared with benign prostate hyperplasia tissue.

[1]  J. Deslypere,et al.  Testosterone and 5α-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene , 1992, Molecular and Cellular Endocrinology.

[2]  D. Chopin,et al.  Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  P. Höglund,et al.  Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[4]  D. Russell,et al.  Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. , 1992, The Journal of clinical investigation.

[5]  R. Rittmaster,et al.  Androgen-Induced Regrowth in the Castrated Rat Ventral Prostate: Role of 5α-Reductase1. , 1999, Endocrinology.

[6]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia , 1998 .

[7]  P. Span,et al.  Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. , 1999, The Journal of urology.

[8]  M. Ohtawa,et al.  Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[9]  S. Frye,et al.  Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. , 1995, Biochemistry.

[10]  T. Wilt,et al.  Chemotherapy for hormone-refractory prostate cancer. , 2006, The Cochrane database of systematic reviews.

[11]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[12]  F. Hamdy.  The prostate cancer prevention trial and its messages. , 2007, European urology.

[13]  D. Tindall,et al.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. , 2004, The Journal of urology.

[14]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[15]  J. Mohler,et al.  268: Biochemical and Pharmacological Evidence for a Third Isozyme of Steroid 5A-Reductase in Prostate Cancer , 2007 .

[16]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[17]  S. Balk,et al.  Androgen receptor as a target in androgen-independent prostate cancer. , 2002, Urology.

[18]  Jun Luo,et al.  Decreased gene expression of steroid 5 alpha‐reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma , 2003, The Prostate.

[19]  P. Boyle,et al.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.

[20]  B. Norlén,et al.  Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue. , 1997, The Journal of clinical endocrinology and metabolism.

[21]  I. Thompson,et al.  5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. , 2003, The Journal of urology.

[22]  J. Isaacs,et al.  Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle. , 1983, Journal of steroid biochemistry.

[23]  G. Andriole,et al.  Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. , 2004, Urology.

[24]  U. Francke,et al.  Characterization and chromosomal mapping of a human steroid 5 alpha-reductase gene and pseudogene and mapping of the mouse homologue. , 1991, Genomics.

[25]  J. Wilson,et al.  Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. , 1992, The Journal of clinical endocrinology and metabolism.

[26]  G. Cunningham,et al.  Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. , 2004, The Journal of clinical endocrinology and metabolism.

[27]  M. Soloway,et al.  Histopathological effects of androgen deprivation in prostatic cancer. , 1996, Seminars in urologic oncology.

[28]  E. Crawford,et al.  The PCPT: New Findings, New Insights, and Clinical Implications for the Prevention of Prostate Cancer , 2006 .

[29]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[30]  M. Schell,et al.  Steroid 5α-Reductase Isozymes I and II in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[31]  R. Serfling,et al.  Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. , 2007, The Journal of urology.

[32]  D. Tindall,et al.  Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. , 2002, Cancer research.

[33]  G. Aumüller,et al.  Differential expression of 5α‐reductase isoenzymes in the human prostate and prostatic carcinomas , 1996, The Prostate.

[34]  M. Gleave,et al.  Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer , 2004 .

[35]  V. Petrow,et al.  The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications , 1986, The Prostate.

[36]  G. Cancel-Tassin,et al.  Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. , 2007, European urology.

[37]  J. Isaacs,et al.  Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers , 2006, Clinical Cancer Research.

[38]  Z. Culig.  Role of the androgen receptor axis in prostate cancer. , 2003, Urology.

[39]  D. Russell,et al.  Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism , 1991, Nature.

[40]  D. Russell,et al.  Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. , 1993, The Journal of clinical investigation.

[41]  L. Johnson,et al.  The Effect of a 5α-Reductase Inhibitor on Androgen Physiology in the Immature Male Rat* , 1989 .

[42]  Daniel Gioeli,et al.  Ras signaling in prostate cancer progression , 2004, Journal of cellular biochemistry.

[43]  P. Febbo,et al.  Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[45]  B. Norlén,et al.  Messenger Ribonucleic Acid Levels of Steroid 5α-Reductase 2 in Human Prostate Predict the Enzyme Activity1 , 2001 .

[46]  E. Vaughan,et al.  Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. , 1992, The Journal of clinical endocrinology and metabolism.

[47]  R. Rittmaster,et al.  The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia , 2007, Prostate Cancer and Prostatic Diseases.

[48]  E. Canby-Hagino,et al.  Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. , 2007, European urology.

[49]  D. Russell,et al.  Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. , 1992, The Journal of biological chemistry.

[50]  P. Kantoff,et al.  Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. , 1997, Urology.

[51]  P. Kantoff,et al.  Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  D. Troyer,et al.  Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer , 2005 .

[53]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[54]  W. E. Farnsworth,et al.  Androgen of the human prostate. , 1976, Endocrine research communications.

[55]  D. Russell,et al.  Expression and regulation of steroid 5α-reductase 2 in prostate disease , 1994 .

[56]  M. Pike,et al.  The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. , 1998, British Journal of Cancer.

[57]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.